Compare AUID & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUID | HOWL |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 18.9M |
| IPO Year | 2014 | 2021 |
| Metric | AUID | HOWL |
|---|---|---|
| Price | $1.10 | $0.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 107.9K | ★ 647.6K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,040,660.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 130.20 | N/A |
| 52 Week Low | $0.84 | $0.33 |
| 52 Week High | $5.82 | $2.23 |
| Indicator | AUID | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 30.92 |
| Support Level | $0.93 | N/A |
| Resistance Level | $1.13 | $0.74 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 32.14 | 8.15 |
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.